Evidence map›Paper›PMID 31405076›Full record

ArticleGenes2019

Integrative Analysis of Cancer Omics Data for Prognosis Modeling.

Shuaichao Wang, Mengyun Wu, Shuangge Ma

Abstract read
In one paragraph

Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Knowledge Generation with Rule Induction in Cancer Omics.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuaichao WangSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Mengyun WuSchool of Statistics and Management, Shanghai University of Finance and Economics, Shanghai 200433, China. wu.mengyun@mail.shufe.edu.cn.
Shuangge MaDepartment of Biostatistics, Yale University, New Haven, CT 06520, USA. shuangge.ma@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Novel methods for identifying genetic interactions in cancer prognosisR01CA204120 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2016 to 2026
$3.5M
Assisted Network-based Analysis of Cancer Gene Expression StudiesR03CA216017 · NCI · YALE UNIVERSITY · PI MA, SHUANGGE · 2017 to 2018
$168k
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA204120NCI NIH HHS R03 CA216017NIH HHS CA216017, CA204120
6 · The paper itself

Abstract

Prognosis modeling plays an important role in cancer studies. With the development of omics profiling, extensive research has been conducted to search for prognostic markers for various cancer types. However, many of the existing studies share a common limitation by only focusing on a single cancer type and suffering from a lack of sufficient information. With potential molecular similarity across cancer types, one cancer type may contain information useful for the analysis of other types. The integration of multiple cancer types may facilitate information borrowing so as to more comprehensively and more accurately describe prognosis. In this study, we conduct marginal and joint integrative analysis of multiple cancer types, effectively introducing integration in the discovery process. For accommodating high dimensionality and identifying relevant markers, we adopt the advanced penalization technique which has a solid statistical ground. Gene expression data on nine cancer types from The Cancer Genome Atlas (TCGA) are analyzed, leading to biologically sensible findings that are different from the alternatives. Overall, this study provides a novel venue for cancer prognosis modeling by integrating multiple cancer types.

Indexed as

Biomarkers, TumorDiagnosis, Computer-AssistedGene Expression Regulation, NeoplasticGenomicsHumansModels, TheoreticalNeoplasmsPrognosisBiomarkers, Tumorintegrative analysismultiple cancer typesomics dataprognosis modeling

Identifiers

PMID31405076
PMCPMC6727084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.